ACTRN12617001187336终止2 期
A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 83
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1.Capable of understanding the content of and able voluntarily to provide a personally signed and dated written informed consent form.
- •2.Stated willingness to comply with all study procedures and availability for the duration of the study.
- •3.Male or female, aged 18-70 years inclusive.
- •4.Clinical diagnosis of type 1 diabetes, defined as at least 2 out of 3 of the following: (i) age of onset < 40 years, (ii) insulin commenced within 1 year of the diagnosis of diabetes, (iii) positive autoantibodies for at least 1 of the antibodies associated with type 1 diabetes (islet cell antibody [ICA], insulin autoantibody [IAA], tyrosine phosphatase–like insulinoma antigen-2 autoantibody [IA-2A], zinc transporter 8 autoantibody (ZnT8 A) and glutamic acid decarboxylase autoantibody [GADA]).
- •5.Established albuminuria, defined as an urine albumin to creatinine ratio (UACR) greater than or equal to 2.5 mg/mmol in men or greater than or equal to 3.5 mg/mmol in women, with
- •(a)the most recent UACR to have been within the albuminuria range and collected within the 12 months before Visit 1, AND
- •(b)at least one other UACR within the albuminuria range in the last 24 months before Visit 1, AND
- •(c)with not more than 1 normal UACR (i.e. <2.5 mg/mmol in men or <3.5 mg/mmol in women) in the 24 months before Visit 1, AND
- •(d)the geometric mean of the 2 UACR tests collected at Visit 1 is in the albuminuria range, greater or equal to 2.5 mg/mmol in men or greater or equal to 3.5 mg/mmol in women.
- •6.eGFR greater or equal to 40 mL/min/1.73 m2, as calculated by the CKD-EPI creat formula, at Visit 1.
- •7.Participants must be taking either ACEI or ARB at a constant dose for at least 13 weeks prior to Visit 1, where the dose of the ACEI or the ARB is considered appropriate for that patient (up to maximum daily dose approved by the TGA) and it is anticipated that the same dose can and will be maintained throughout the course of the study. The only exception is if the participant has a documented intolerance to RAS blockade, such that neither an ACEI nor ARB are used or intended to be used for the duration of the study. The nature of the intolerance (e.g. hyperkalaemia, hypotension) must be documented by the Investigator in the study record at Visit 1. Combination therapy using an ACEI and an ARB is not permitted.
- •8.Participants taking any blood pressure-lowering medications in addition to an ACEI or ARB, including diuretics, must be on a stable dose for at least 13 weeks prior to Visit 1.
- •9.Ability to take oral medication and be willing to adhere to the medication regimen.
- •10.Willing to practice highly effective methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) during the screening period, while taking investigational product and for at least 90 days after the last dose of investigational product is ingested. Women of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), and are not postmenopausal for at least 1 year. Furthermore, male study participants must also not donate sperm from day of randomisation until 90 days after the last dose of investigational product.
排除标准
- •1.History of type 2 diabetes.
- •2.HbA1c at Visit 1 greater or equal to 10.0% (greater or equal to 86 mmol/mol).
- •3.Chronic kidney disease due to a documented history of non-diabetic kidney disease(s), except for hypertensive nephropathy, which is acceptable. Therefore, the chronic kidney disease must be due to diabetic kidney disease, with or without hypertensive kidney disease.
- •a.Diagnostic or interventional procedure requiring a contrast agent within 4 weeks of the first screening visit.
- •b.Untreated urinary tract infection at Visit 1 that would impact urinary protein levels.
- •c.History of renal transplant or other solid organ transplant, or planned renal transplant or other solid organ transplant during the study.
- •d.A history of acute renal dialysis or acute kidney injury (defined according to the Kidney Disease: Improving Global Outcomes [KDIGO] definition) within 13 weeks of Visit 1.
- •4.Body mass index (BMI) <18.5 kg/m2 or >40 kg/m2.
- •5. eGFR <40 ml/min/1.73m2, as calculated by the CKD-EPI creat formula.
- •6.Alteration in anti-hypertensive therapy within 13 weeks prior to Visit 1, including change in dosing with ACEI or ARB.
- •7.Women who are lactating, pregnant, or intend to become pregnant during the course of the study.
- •8.Participants with clinically significant liver disease or elevated liver enzymes, defined as alkaline phosphatase or transaminase (alanine aminotransferase [ALT] or aspartate aminotransferase [AST]) levels >3 × the upper limit of normal (ULN) measured at Visit 1 or bilirubin >1.5 x the ULN measured at Visit 1.
- •9.Inadequately controlled arterial blood pressure, defined as SBP >160 mmHg at Visit 1 or DBP > 95 mm Hg at Visit 1.
- •10.Current history of thyroid disorder requiring thyroid hormone replacement therapy, unless the dose of thyroid hormone replacement has been stable for at least 4 weeks prior to Visit 1 and the thyroid stimulating hormone (TSH) value is not greater than the ULN at Visit 2.
- •11.History of active cardiovascular disease defined as the occurrence of the following events or conditions within the 13 weeks preceding Visit 1: acute myocardial infarction; unstable angina pectoris; stroke, including a transient ischemic attack; a coronary revascularisation procedure; congestive heart failure New York Health Association (NYHA) Class III or IV.
- •12.A personal or family history of long QT syndrome.
- •13.Evidence of any of the following cardiac conduction abnormalities during the screening period: A QTc Fridericia interval >450 milliseconds for males and >470 milliseconds for females; second or third degree AV block not successfully treated with a pacemaker. Fridericia’s correction QTc = QT/RR0.33.
- •14.A history of bone marrow disorder, including aplastic anaemia, or marked anaemia at Visit 1 defined as haemoglobin < 100 g/L.
- •15.Participants with a history of treatment for neoplastic disease within 5 years prior to Visit 1. The exceptions allowed are adequately treated basal or squamous cell carcinoma of the skin, adequately treated in situ carcinomas of the cervix, prostate, ductal breast, or superficial bladder cancer stage 0.
- •16.Current history of drug or alcohol abuse, as assessed by the site Investigator.
- •17.The occurrence of any acute infection requiring systemic antibiotic therapy within the 2 weeks prior to Visit 1, or known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection.
- •18.Use of the following medications within 4 weeks of
研究者
相似试验
尚未招募
4 期
A study to compare efficacy of injection of Ropivacaine plus Fentanyl and Ropivacaine plus Tramadol in spinal anaesthesiaCTRI/2023/06/053362Pacific medical college and hospital
尚未招募
不适用
A study comparing 2 drugs in reversal of general anaesthesiaCTRI/2023/10/058419SIMS hospitals, Department of anaesthesiology and pain management
招募中
2 期
Effects of Vitamin E Delta-tocotrienol supplementation in Nonalcoholic Fatty Liver Disease (NAFLD)onalcoholic fatty liver disease (NAFLD)SLCTR/2015/023Armed Forces Institute of Pathology, Pakistan
已完成
不适用
A randomized, placebo-controlled, double blind volunteer study into the effect of milk ingredients on gastroenteritis caused by an attenuated E. coli.gastroenteritisNL-OMON37279Arla Foods Ingredients Group P/S60
暂停
2 期
A study on the efficacy of Tulasi-Ashwagandhadi Herbal Drops on Oxygen Saturation (SPO2) in the management of COVID-19 affected cases.CTRI/2021/09/036826Charak Hanf Pvt Ltd